Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma

<div>PET/CT scan of the abdomen. (a) One month prior to the first cycle of nivolumab: multiple intrahepatic lesions. (b) Day 22 after the first cycle of nivolumab: significant hepatomegaly due to hepatitis, significant increased metabolic activity of the entire liver, and new abdominal ascites. The PET/CT scan of the patient abdomen depicts the changes in the patient’s liver before and after starting nivolumab. The second picture shows the large size of the liver when the patient developed autoimmune hepatitis.</div>

Case Reports in Oncological Medicine

fig2

Figure 2

Figure 2: Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma 

Figure 2 | Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma 